53 results
Page 2 of 3
6-K
EX-99.1
qw6hxmq4251tf
3 May 23
Annual General Meeting of Shareholders to Be
5:25pm
6-K
EX-99.2
dqqd1ca2dqos
15 Aug 22
Current report (foreign)
6:16pm
F-3
uieaa czf05zs3
3 Sep 21
Shelf registration (foreign)
4:34pm
POS AM
ranvlpvb4 hgd
3 Sep 21
Prospectus update (post-effective amendment)
4:31pm
424B3
s09rbobkvgxmsp8ipii9
9 Apr 21
Prospectus supplement
4:36pm
F-1
xpomgjvas7 syhil
1 Apr 21
Registration statement (foreign)
5:29pm
20-F
EX-12.1
r975x
18 Mar 21
Annual report (foreign)
9:03am
20-F
EX-12.2
j9zficy8cm
18 Mar 21
Annual report (foreign)
9:03am
20-F
55w77w51nt6
18 Mar 21
Annual report (foreign)
9:03am
6-K
EX-10.1
031 5rociraqr
9 Mar 21
PainReform Announces $6.0 Million Private Placement
4:15pm
6-K
EX-99.1
wk7xiimwybl7eg7jx8t
4 Jan 21
PainReform Announces Appointment of Lotus Clinical Research as CRO for Phase 3 Clinical Trial of PRF-110
4:16pm
424B3
4l33c35 x56
25 Nov 20
Prospectus supplement
11:12am
6-K
EX-99.1
htgkg
25 Nov 20
PainReform Appoints Senior Pharmaceutical Executive and Finance Veteran Ilan Hadar as Chief Executive Officer
10:08am
6-K
EX-99.1
wq0uaz8f0q61
13 Nov 20
Report of Foreign Private Issuer
6:09am
6-K
EX-99.1
vzhd oawh
9 Nov 20
PainReform Welcomes Senior Pharmaceutical Executive and Venture Capitalist Augustine Lawlor to Board of Directors
10:30am
6-K
EX-99.1
dkjdrb vjt4xksj4
19 Oct 20
PainReform Highlights Surgical Advantages of PRF-110
1:37pm
424B3
fti32bko7t0f 4lpb
30 Sep 20
Prospectus supplement
4:42pm